CL2016001763A1 - Nr2b selective antagonists - Google Patents
Nr2b selective antagonistsInfo
- Publication number
- CL2016001763A1 CL2016001763A1 CL2016001763A CL2016001763A CL2016001763A1 CL 2016001763 A1 CL2016001763 A1 CL 2016001763A1 CL 2016001763 A CL2016001763 A CL 2016001763A CL 2016001763 A CL2016001763 A CL 2016001763A CL 2016001763 A1 CL2016001763 A1 CL 2016001763A1
- Authority
- CL
- Chile
- Prior art keywords
- selective antagonists
- nr2b selective
- nr2b
- disease
- pirrolidin
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000034527 Retinoid X Receptors Human genes 0.000 abstract 1
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPUSTOS DERIVADOS DE PIRROLIDIN-2-ONA SUSTITUIDOS, ANTAGONISTAS SELECTIVOS DE NR2B; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; Y METODO PARA EL TRATAMIENTO DE DEPRESION, ENFERMEDAD DE ALZHEIMER, DOLOR NEUROPATICO O ENFERMEDAD DE PARKINSON.COMPOUNDS DERIVED FROM PIRROLIDIN-2-ONA SUBSTITUTED, SELECTIVE ANTAGONISTS OF NR2B; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM; AND METHOD FOR THE TREATMENT OF DEPRESSION, ALZHEIMER'S DISEASE, NEUROPATHIC PAIN OR PARKINSON'S DISEASE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925363P | 2014-01-09 | 2014-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001763A1 true CL2016001763A1 (en) | 2017-02-10 |
Family
ID=52463126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001763A CL2016001763A1 (en) | 2014-01-09 | 2016-07-08 | Nr2b selective antagonists |
Country Status (28)
| Country | Link |
|---|---|
| US (10) | US9221796B2 (en) |
| EP (1) | EP3092224B1 (en) |
| JP (1) | JP6543259B2 (en) |
| KR (1) | KR102311518B1 (en) |
| CN (1) | CN106061961B (en) |
| AR (1) | AR099071A1 (en) |
| AU (1) | AU2015205001A1 (en) |
| CA (1) | CA2936293A1 (en) |
| CL (1) | CL2016001763A1 (en) |
| DK (1) | DK3092224T3 (en) |
| EA (1) | EA201691413A1 (en) |
| ES (1) | ES2693250T3 (en) |
| HR (1) | HRP20181585T1 (en) |
| HU (1) | HUE041986T2 (en) |
| IL (1) | IL246599A0 (en) |
| LT (1) | LT3092224T (en) |
| MX (1) | MX2016008898A (en) |
| PE (1) | PE20160933A1 (en) |
| PL (1) | PL3092224T3 (en) |
| PT (1) | PT3092224T (en) |
| RS (1) | RS57830B1 (en) |
| SG (1) | SG11201605618WA (en) |
| SI (1) | SI3092224T1 (en) |
| SM (1) | SMT201800619T1 (en) |
| TR (1) | TR201815579T4 (en) |
| TW (1) | TWI640515B (en) |
| UY (1) | UY35947A (en) |
| WO (1) | WO2015105772A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| CN107849010B (en) * | 2015-06-01 | 2021-11-09 | 卢郡控股(开曼)有限公司 | 3, 3-difluoropiperidine carbamate heterocycles as NR2B NMDA receptor antagonists |
| WO2017066368A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| KR20180063306A (en) * | 2015-10-14 | 2018-06-11 | 브리스톨-마이어스 스큅 컴퍼니 | Selective NR2B antagonist |
| WO2018098128A1 (en) | 2016-11-22 | 2018-05-31 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| CN108203404A (en) * | 2018-03-02 | 2018-06-26 | 上海博邦医药科技有限公司 | (R) synthetic method of -3- Phenylpiperidines or/and the chiral intermediate of (S) -3- Phenylpiperidines and Ni Lapani |
| US10781172B2 (en) | 2018-06-21 | 2020-09-22 | Northwestern University | Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles |
| WO2024197289A1 (en) * | 2023-03-22 | 2024-09-26 | Gilgamesh Pharmaceuticals, Inc. | Negative allosteric modulators of glun2b receptors and methods of making and using the same |
| WO2025113519A1 (en) * | 2023-11-28 | 2025-06-05 | 成都地奥制药集团有限公司 | Lactam ring compound and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2744448B1 (en) | 1996-02-02 | 1998-04-24 | Pf Medicament | NOVEL PIPERIDINES DERIVED FROM ARYL PIPERAZINE, AS WELL AS THEIR PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS MEDICAMENTS |
| AU3818900A (en) | 1999-04-14 | 2000-11-02 | F. Hoffmann-La Roche Ag | Process for the preparation of substituted piperidines |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| IL152424A0 (en) * | 2000-04-26 | 2003-05-29 | Warner Lambert Co | Cyclohexylamine derivative as subtype selective nmda receptor antagonist |
| JPWO2003035641A1 (en) | 2001-10-22 | 2005-02-10 | 塩野義製薬株式会社 | New carbamoylpyrrolidone derivatives |
| ATE403651T1 (en) | 2003-06-04 | 2008-08-15 | Merck & Co Inc | 3-FLUORO-PIPERIDINE AS NMDA/NR2B ANTAGONISTS |
| MXPA06003748A (en) | 2003-10-08 | 2006-06-14 | Pfizer | Fused lactam compounds. |
| JPWO2007099828A1 (en) | 2006-02-23 | 2009-07-16 | 塩野義製薬株式会社 | Nitrogen-containing heterocyclic derivatives substituted with cyclic groups |
| JP2010532382A (en) * | 2007-06-29 | 2010-10-07 | エモリー・ユニバーシテイ | NMDA receptor antagonist for neuroprotection |
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
-
2015
- 2015-01-05 US US14/589,205 patent/US9221796B2/en active Active
- 2015-01-06 CN CN201580012735.9A patent/CN106061961B/en not_active Expired - Fee Related
- 2015-01-06 WO PCT/US2015/010262 patent/WO2015105772A1/en not_active Ceased
- 2015-01-06 CA CA2936293A patent/CA2936293A1/en not_active Abandoned
- 2015-01-06 RS RS20181296A patent/RS57830B1/en unknown
- 2015-01-06 JP JP2016545819A patent/JP6543259B2/en not_active Expired - Fee Related
- 2015-01-06 SI SI201530408T patent/SI3092224T1/en unknown
- 2015-01-06 KR KR1020167021356A patent/KR102311518B1/en not_active Expired - Fee Related
- 2015-01-06 LT LTEP15703328.3T patent/LT3092224T/en unknown
- 2015-01-06 PE PE2016001107A patent/PE20160933A1/en not_active Application Discontinuation
- 2015-01-06 AU AU2015205001A patent/AU2015205001A1/en not_active Abandoned
- 2015-01-06 HR HRP20181585TT patent/HRP20181585T1/en unknown
- 2015-01-06 MX MX2016008898A patent/MX2016008898A/en unknown
- 2015-01-06 EA EA201691413A patent/EA201691413A1/en unknown
- 2015-01-06 TR TR2018/15579T patent/TR201815579T4/en unknown
- 2015-01-06 ES ES15703328.3T patent/ES2693250T3/en active Active
- 2015-01-06 PL PL15703328T patent/PL3092224T3/en unknown
- 2015-01-06 EP EP15703328.3A patent/EP3092224B1/en active Active
- 2015-01-06 SG SG11201605618WA patent/SG11201605618WA/en unknown
- 2015-01-06 HU HUE15703328A patent/HUE041986T2/en unknown
- 2015-01-06 SM SM20180619T patent/SMT201800619T1/en unknown
- 2015-01-06 DK DK15703328.3T patent/DK3092224T3/en active
- 2015-01-06 PT PT15703328T patent/PT3092224T/en unknown
- 2015-01-08 TW TW104100592A patent/TWI640515B/en not_active IP Right Cessation
- 2015-01-09 AR ARP150100065A patent/AR099071A1/en unknown
- 2015-01-09 UY UY0001035947A patent/UY35947A/en unknown
- 2015-10-13 US US14/882,041 patent/US20160081995A1/en not_active Abandoned
-
2016
- 2016-07-04 IL IL246599A patent/IL246599A0/en unknown
- 2016-07-08 CL CL2016001763A patent/CL2016001763A1/en unknown
-
2017
- 2017-05-25 US US15/604,904 patent/US20170258777A1/en not_active Abandoned
- 2017-09-15 US US15/706,172 patent/US20180000807A1/en not_active Abandoned
- 2017-12-19 US US15/846,672 patent/US20180110766A1/en not_active Abandoned
-
2018
- 2018-05-04 US US15/971,067 patent/US20180250283A1/en not_active Abandoned
- 2018-12-19 US US16/225,850 patent/US20190117638A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,831 patent/US20190314358A1/en not_active Abandoned
-
2020
- 2020-01-30 US US16/777,114 patent/US20200163949A1/en not_active Abandoned
- 2020-09-04 US US17/012,781 patent/US20210121453A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001763A1 (en) | Nr2b selective antagonists | |
| CL2018000542A1 (en) | New phenoxymethyl derivatives. | |
| MX2022009148A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES. | |
| DOP2017000048A (en) | AMINOPIRIMIDINYL COMPOUNDS AS JAK INHIBITORS. | |
| CL2016002072A1 (en) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease | |
| BR112018011709A2 (en) | bicyclic pad4 inhibitors | |
| EA201692201A1 (en) | CONNECTIONS AND COMPOSITIONS AS AN AGONISTS OF TOLL-LIKE RECEPTOR 7 | |
| CL2018000596A1 (en) | New bicyclic compounds as atx inhibitors | |
| UY37134A (en) | HETEROARILE COMPOUNDS AND COMPOSITIONS THAT CONTAIN USEFUL AS PAD4 INHIBITORS | |
| MX2018003388A (en) | Farnesoid x receptor agonists and uses thereof. | |
| MX378998B (en) | 4-HYDROXY-3-(HETEROARYL)PYRIDIN-2-ONE APELIN RECEPTOR AGONISTS (APJ) FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS. | |
| CL2016001595A1 (en) | Gpr6 tetrahydropyridyrazine modulators. | |
| CL2016002169A1 (en) | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders. | |
| BR112016018062A8 (en) | therapeutic compounds, pharmaceutical composition and uses | |
| CL2016002084A1 (en) | Compounds derived from cyclopentane 1,2 substituted as orexin receptor antagonists. | |
| MX389001B (en) | SESTRIN-GATOR2 INTERACTION MODULATORS AND THEIR USES. | |
| EA201791454A1 (en) | DRUG FORMS FOR TRANSDERMAL ADMINISTRATION | |
| MX394123B (en) | AMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USING THEM | |
| CO2018008249A2 (en) | Therapeutic compositions and methods for the treatment of hepatitis b | |
| CL2019000049A1 (en) | Processes for the preparation of 4-alkoxy - (acyl or aquyl) oxy-picolinamide. | |
| PL3424499T3 (en) | Pharmaceutical composition for the treatment of neuropathic pain | |
| JO3456B1 (en) | ferrotioxetine pyroglutamate | |
| DK3302573T3 (en) | COMPOSITION FOR THE TREATMENT OF BRAIN LESSIONS | |
| UA117779C2 (en) | POINTS AS GPR6 MODULATORS | |
| DK3403674T3 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN |